StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 10/30/2014, (NASDAQ:MRK), $56.2 +0.35, +0.63%, "BUY" Merck & Compan Stock
 




  
  

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   10/30/2014   StockRing.com recommends to   "BUY"   MRK   stock at current price of   $56.2.
Today MRK stock opened at $56.02 and was trading in the daily range of $ 97645 per share.
Merck & Compan (NASDAQ:MRK) Market capitalization is $162.1B. MRK average daily volume is N/A.
On last trading session MRK stock traded 12,497,196 shares. Also the Short Ratio for (NASDAQ:MRK) stock is 43.550B.
Last year Merck & Compan(NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $56.01 on revenue of $3.35.
MRK 50-Day Moving Average is $15.950B vs. $56.2 now and 200-Day Moving Average is $58.26 vs. $56.2.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "HOLD".  S&P 500 is "HOLD" on  5/16/2014
--------------------------------------------------------------------------------------------------------------------
MRK Earnings Per Share - EPS (ttm) is 1.9. MRK Stock Price Per Earnings ratio - P/E is 29.43.
Merck & Compan(NASDAQ:MRK) stock pays a dividend of $ " per share which is a yield of "NYSE"%.
On average analysts predict that One Year Target Estimated price for MRK stock is $57.98.
In the last 52 weeks MRK stock was trading in the range of $44.62 - 61.33.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

BUY  DOW 30+: FF  FTK  PTEN  NR  EXH     ENERGY: ADMA  RNG  CDW  CBA  BLUE     HEALTH: ACWX  EPHE  FM  DVYA  AOM 
      FINANCE: XLK  DWX  BWZ  GII  SCPB     SERVICES: UST  MLPX  BRAQ  YCL  EMFM     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: PVA  PWE  FOE  GNE  EOX     ENERGY: RMAX  SEAS  NBCB  PETX  VOYA     HEALTH: ITA  ICLN  EIRL  SCZ  PICK 
      FINANCE: XME  XSW  KBE  EWO  BAL     SERVICES: VIXM  EEV  UVXY  QID  AGQ     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



10/30/2014  Thursday, October 30, 2014 (Irvine, California) Today StockRing.com Recommendation is to "BUY"for Merck & Compan (NASDAQ:MRK) Stock. MRK stock opening price was $56.02 per share. Current price of NASDAQ:MRK Stock is $56.2 per share and it is $+0.35, (+0.63%) today and it was trading in the daily range of $97645 per share. Current Bid Price for (NASDAQ:MRK) stock is $3.15 and the Ask Price is $55.74. In the last 52 weeks MRK stock was trading in the range of $44.62 - 61.33. 50-Day Moving Average for (NASDAQ:MRK) stock is $15.950B and 200-Day Moving Average is $58.26. On average analysts predict that One Year Target Estimated price for (NASDAQ:MRK) stock is $57.98.

Merck & Compan (NASDAQ:MRK) is rated as a buy on 9/10/2014 1:20:56 AM.

Merck & Compan (NASDAQ:MRK) Market capitalization is $162.1B. (NASDAQ:MRK) stock average daily volume is N/A shares per day. However, on last trading session of Oct 29, 2012 MRK stock traded 12,497,196 shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:MRK) stock is 43.550B. On previous trading session MRK Stock closed at $55.85 per share.

Last year Merck & Compan (NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $56.01 on total revenue of $3.35. Earnings Per Share - EPS (ttm) for MRK stock is 1.9. Also, (NASDAQ:MRK) Stock Price Per Earnings ratio - P/E is 29.43. Thus, (NASDAQ:MRK) Stock Price/Sales (ttm) ratio is 63.30 and Price/Book (mrq) ratio is 3.70.

(NASDAQ:MRK) Stock pays a dividend of $ " per share which is a yield of "NYSE"%. So at this time (NASDAQ:MRK) Stock maintains Trailing Annual Dividend Rate at 2.40.


StockRing Recommendations for Merck & Compan (NASDAQ:MRK) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=MRK

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

10/30/2014 1 Year Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, October 30, 2014
  
1 Year MRK 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
10/30/2014 5 days Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, October 30, 2014
  
5 Days MRK 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

10/30/2014 Stock market price quote data for Merck & Compan (NASDAQ:MRK) Stock on Thursday, October 30, 2014

Last Trade: 56.2
Trade Time: Oct 29
Change: +0.35, (+0.63%)
Prev Close: 55.85
Open: 56.02
Bid: 3.15
Ask: 1.76
1y Target Est: $57.98
50-Day Moving Average: 15.950B
200-Day Moving Average:
58.26
Short Ratio: 43.550B
Trailing Annual Dividend Rate: 2.40
Day's Range: 97645
52wk Range: 44.62 - 61.33
Volume: 12,497,196
Avg Vol: N/A
Market Cap: 162.1B
P/E (ttm): 29.43
EPS (ttm): 1.9
Div & Yield: " ("NYSE"%)
Revenue (ttm): 3.35
Earnings before Tax (EBITDA) (ttm): 56.01
Price/Sales (ttm): 63.30
Price/Book (mrq): 3.70
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

MERCK CO INC(NYSE: MRK) Company Information

Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station, NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com

MERCK CO INC(NYSE: MRK) DETAILS

MERCK CO INC(NYSE: MRK) Index Membership: Dow Jones Composite Dow Industrials S&P 100 S&P 500 S&P 1500 Super Comp
MERCK CO INC(NYSE: MRK) Sector: Healthcare
MERCK CO INC(NYSE: MRK) Industry: Drug Manufacturers - Major
MERCK CO INC(NYSE: MRK) Full Time Employees: 52,700

MERCK CO INC(NYSE: MRK) BUSINESS SUMMARY

Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

MERCK CO INC(NYSE: MRK) KEY EXECUTIVES

Mr. Richard T. Clark , 63 Exec. Chairman, Chief Exec. Officer and Pres $ 4.03M $ 0

Mr. Peter N. Kellogg , 52 Chief Financial Officer and Exec. VP $ 1.60M $ 0

Mr. Kenneth C. Frazier , 54 Exec. VP and Pres of Global Human Health $ 2.00M $ 0

Dr. Peter Kim Ph.D., 50 Exec. VP and Pres of Merck Research Laboratories $ 1.91M $ 0

Mr. Bruce N. Kuhlik , 52 Exec. Vice president and Gen. Counsel $ 1.25M $ 0



10/30/2014 Latest stock market news data for Merck & Compan (NASDAQ:MRK) Stock on Thursday, October 30, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Motley Fool - Oct 27, 2014
Big pharma giant Merck (NYSE: MRK ) hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along ...
Merck & Co., Inc. Posts Lower Q3 Results; EPS Beats View; Revenue Misses ... - Dividend.com
Merck & Co., Inc. (MRK) Issues FY14 Earnings Guidance - Mideast Time
Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates
ValueWalk - Oct 27, 2014
Merck & Co., Inc. (NYSE:MKR) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 billion in revenue.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on October 27
Equities.com - Oct 27, 2014
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 2.01%. The DJIA closed at 16,817.90, which is a 0.07% change from the previous day's close.
A Quick Look at Merck & Co. Inc.'s Drug Development Pipeline
Motley Fool - Oct 13, 2014
Today, I'd suggest we take a closer look at Merck's (NYSE: MRK ) drug development pipeline in order to get a better idea of how well the company is preparing for its future beyond patent expirations, as well as note which handful of developing drugs ...
Merck & Co. Inc. (MRK) Pulled Back After Q3 Revenues Disappoint
RTT News - Oct 28, 2014
Merck & Co. Inc. (MRK: Quote) reported third quarter adjusted EPS of $0.90 Monday morning, down from $0.92 a year ago. Revenues declined 4 percent to $10.56 billion from $11.03 billion last year.
Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics
Benzinga - Oct 28, 2014
On CNBC's Fast Money, Stephanie Link said that Merck & Co., Inc. (NYSE: MRK) posted a fine quarter although the company missed revenue expectations and it narrowed its full year forecast.
Uptrend Stocks At Street: Armstrong World Industries, Inc. (NYSE:AWI), Merck ... - Street Newswire (registration)
Equities in Focus - Merck & Co., Inc. (NYSE:MRK), Compugen Ltd. (USA ...
Street Newswire (registration) - Oct 27, 2014
Merck & Co., Inc. (NYSE:MRK) said the U.S. Food and Drug Administration has granted a Breakthrough Therapy Designation to its Keytruda drug to treat non-small cell lung cancer.
Merck Conference Call Highlights
Benzinga - Oct 27, 2014
Merck & Co., Inc. (NYSE: MRK) reported its third quarter earnings on Monday. Shares of the company are down 2 percent. Below are some key highlights from its conference call.
Bayer closes acquisition of consumer care business of Merck & Co., Inc. for ...
MarketWatch - Oct 1, 2014
Bayer has completed the global acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals.
Company Update: Merck & Co Inc (NYSE:MRK) - Merck Completes Sale of ... - Jutia Group
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on October 28
Equities.com - Oct 28, 2014
Shares of Merck & Co. Inc. led all laggers on the Dow Tuesday with a decline of 1.06%. The DJIA closed at 17,005.80, which is a 1.12% change from the previous day's close.

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


10/30/2014 News from StockRing Blog about Merck & Compan (NASDAQ:MRK) Stock on Thursday, October 30, 2014



Copyright © 2014 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds   Form

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.